Premium
Pharmacokinetics and dynamics of famotidine in patients with renal failure.
Author(s) -
Gladziwa U.,
Klotz U.,
Krishna DR,
Schmitt H.,
Glockner WM,
Mann H.
Publication year - 1988
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1988.tb05282.x
Subject(s) - famotidine , medicine , continuous ambulatory peritoneal dialysis , renal function , urology , volume of distribution , hemodialysis , peritoneal dialysis , dialysis , pharmacokinetics , hemofiltration , kidney disease , endocrinology
1. Famotidine, a new histamine H2‐receptor antagonist was administered intravenously (20 mg) to 22 patients with end stage renal disease during a dialysis free interval (n = 6) and during different blood purification processes including haemodialysis (HD; n = 4), intermittent haemofiltration (HF; n = 4), continuous haemofiltration (CHF; n = 4) and continuous ambulatory peritoneal dialysis (CAPD; n = 4). The plasma, the dialysate/filtrate and the urine concentrations of famotidine were analysed by h.p.l.c. 2. In addition, intra‐gastric pH was measured by a long‐term‐pH probe in seven patients with renal failure and in six patients with normal renal function (control group) following 20 mg famotidine. 3. A 7 to 10 fold prolongation of famotidine's elimination half‐life (27.2 +/‐ 8.5 h; mean +/‐ s.d.) was observed in patients with renal failure as compared with the half‐life (2.6‐3.6 h) in subjects with normal renal function. 4. Total body clearance (CL) and volume of distribution (V) were found to be 33.5 +/‐ 10.1 ml min‐1 and 1.3 +/‐ 0.7 l kg‐1, respectively in patients with end‐ stage renal failure. 5. Blood purification processes have shown considerable variation in clearing famotidine from the body: 16.4 +/‐ 8.9 and 6.0 +/‐ 2.9% of the administered dose in HD with polysulphone and cuprophan membranes respectively, 7.7 +/‐ 5.2% in HF with a polyacrylonitrile membrane (each for 5 h), 4.5 +/‐ 1.1% in CAPD and 16.2 +/‐ 4.9% in CHF with a polysulphone membrane within 24 h.(ABSTRACT TRUNCATED AT 250 WORDS)